Menu
Recruiting NCT07148908

Animal and Microbial-based Dietary Protein Efficiency in Adults

No phase Interventional Protein Metabolism

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Yeast Protein Supplement, Whey Protein Isolate Supplement, Collagen Hydrolysate Supplement.
Who it may be relevant to
Registry conditions: Protein Metabolism. Basic parameters: 18 years — 45 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The Effects of Animal- and Microbial-based Protein Sources on Whole-body Protein Metabolism in Healthy Adults

Overview

Given the relatively high carbon footprint and sustainability of animal-based proteins, there is a growing interest in determining the nutritional quality non-animal-based protein sources. The overall objective of this investigation is to examine the impact of different animal and microbial-based protein sources to support whole body protein synthesis in adults. To do this, investigators will employ a 'breath test' method developed in our laboratory as well as urine sampling. The results of this study will allow us to better understand the impact of dietary protein quality for maintaining health and body protein mass in adults.

Interventions

  • Dietary supplement Yeast Protein Supplement
    Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
  • Dietary supplement Whey Protein Isolate Supplement
    Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks
  • Dietary supplement Collagen Hydrolysate Supplement
    Each protein will be consumed at 0.9g/kg/d in n=8 hourly drinks

Primary outcome measures

  • 1. Phenylalanine excretion (umol/kg/h) [Time frame: 8 hours]
  • Phenylalanine oxidation (umol/kg/h) [Time frame: 8 hours]

Eligibility criteria

Inclusion criteria

  • Healthy, male and female, recreationally-active participants.
  • Healthy will be defined as screened by the PAR-Q+ (Appendix B) and The Physical Activity Readiness Questionnaire (Appendix C).
  • Participants will be aged 18-45 years old.
  • Participants are willing to abide by the compliance rules of this study.
  • Self-reported regular menstrual cycle (25-35d) within the last 3 months (female participants).
  • Use of monophasic combined oral contraceptives (COC) containing 21 active pills (e.g., Yaz, Marvelon, Cyclen, etc.; the brand of COC will be recorded) (female participants).

Exclusion criteria

  • Inability to adhere to any of the compliance rules judged by principal investigator (e.g. dairy protein or yeast allergy).
  • Self-reported regular tobacco use.
  • Self-reported illicit drug use (e.g., growth hormone, testosterone, etc.).
  • Individuals who have participated in studies within the past year involving any of the stable isotopes in the study.
  • Use of multiphasic COCs due to the difficulty of controlling for hormonal fluctuations in such formulations (female participants).
  • Use of COCs containing >21 active pills per cycle due to potential differences in their effect on metabolism (female participants).
  • Use of other forms of hormonal contraception (e.g., progestin-only pill, hormonal IUD, intravaginal ring) (female participants).
  • Not currently or previously (in the past 6 months) on a vegan diet

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Single blind
Primary purpose
Basic science

Study locations

Canada · 1 center
  • Kinesiology & Physical Education — Toronto

Identifiers

NCT: NCT07148908 · REB00048239

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗